News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard Nov 1, 2022 Corporate and finance Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022 Download Oct 20, 2022 COVID-19Seasonal influenza Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022 Download Oct 19, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Download Oct 19, 2022 COVID-19 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster for Adults Download Oct 13, 2022 COVID-19Seasonal influenza Novavax COVID-19-Influenza Combination Vaccine Candidate Induced Antibody and T-Cell Responses Against SARS-CoV-2 and Homologous and Heterologous Influenza Strains Download Oct 12, 2022 COVID-19 Novavax Prototype COVID-19 Vaccine Data Support Homologous and Heterologous Boosting and Suggest Benefit Against Variants Download Oct 10, 2022 Stanley Erck Opening Statement European Parliament – COVI Committee Hearing Delivered: October 10, 2022 Download Oct 10, 2022 COVID-19Seasonal influenza Novavax to Share New Data from Growing Vaccine Portfolio at World Vaccine Congress Europe 2022 Download Oct 10, 2022 Statement Novavax and SK bioscience File a Post Approval Change Application in South Korea for Nuvaxovid™ COVID-19 Vaccine as a Booster in Adults Aged 18 and Older Download Oct 10, 2022 Statement Switzerland’s Federal Office of Public Health Recommends Novavax Nuvaxovid™ COVID-19 Vaccine as a Booster in Adults Aged 18 and Older Download Show 5102550100 per page«123456789…46»